Newsroom
Sorted by: Latest
-
QXO Stock Alert: Halper Sadeh LLC is Investigating Whether QXO, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of QXO, Inc. (NYSE: QXO) and TopBuild Corp.Halper Sadeh encourages QXO shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.The investigation concerns whether QXO and its board of directors violated the federal securities laws and/or breached their fid...
-
AST SpaceMobile Addresses Today’s Orbital Launch of BlueBird 7 on the New Glenn Launch Vehicle
MIDLAND, Texas--(BUSINESS WIRE)--AST SpaceMobile, Inc. ("AST SpaceMobile") (NASDAQ: ASTS), the company building the first and only space-based cellular broadband network accessible directly by everyday smartphones, designed for both commercial and government applications, addresses today’s orbital launch of BlueBird 7 on the New Glenn launch vehicle. During the New Glenn 3 mission, BlueBird 7 was placed into a lower than planned orbit by the upper stage of the launch vehicle. While the satellit...
-
PYPL Deadline: Rosen Law Firm Urges PayPal Holdings, Inc. (NASDAQ: PYPL) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of PayPal Holdings, Inc. (NASDAQ: PYPL) common stock between February 8, 2024 and February 2, 2026, inclusive (the “Class Period”). PayPal enables digital payments. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that PayPal Holdings...
-
Renee Russo named Exit Planner of the Year at 2026 Exit Planning Summit
CLEVELAND--(BUSINESS WIRE)--Exit Planning Institute® (EPI) announced today the winners of the annual Excellence in Exit Planning Awards....
-
QXO to Acquire TopBuild for $17 Billion
GREENWICH, Conn. & DAYTONA BEACH, Fla.--(BUSINESS WIRE)--QXO, Inc. (NYSE: QXO) today announced that it has entered into a definitive agreement to acquire TopBuild Corp. (NYSE: BLD) (“TopBuild”) for approximately $17 billion, significantly expanding QXO’s scale and capabilities across the building products value chain. The transaction is expected to be immediately and substantially accretive to the company’s earnings. TopBuild is the largest distributor and installer of insulation and related bu...
-
Block Blast! Brings Its Brand to Coachella as Visibility Grows in the U.S.
LOS ANGELES--(BUSINESS WIRE)--On April 17, Block Blast! appeared at Coachella through a branded ad truck and aerial banner activation. ...
-
Impact Capital Group Releases New Analysis on Real Estate’s Growing Influence on Lower Middle Market M&A Transaction Outcomes
LOS ANGELES--(BUSINESS WIRE)--Impact Capital Group, Inc. (“Impact”), a lower middle market investment banking and valuation firm, today announced the release of a new analysis examining how owned and leased real estate can materially influence private company sale transactions. The analysis, titled “The Real Estate Variable: How Real Estate Shapes, Complicates, and Sometimes Derails Lower Middle Market M&A,” draws on anonymized case studies from Impact’s advisory experience and highlights t...
-
Lundbeck Presents New Data at AAN 2026 Highlighting Real-World Changes in Migraine-Related Cognitive Symptoms After Starting VYEPTI® (eptinezumab-jjmr)
DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI...
-
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric and neurological disorders, today issued the following statement supporting the newly signed White House Executive Order aimed at accelerating research, development, and responsible access to innovative treatments for serious mental illness, including emerging psychedelic medi...
-
HSS Studies Contribute Early Evidence to Help Guide Emerging Perioperative Considerations for Patients Using GLP‑1 Medications
PHOENIX--(BUSINESS WIRE)--At this year’s American Society of Regional Anesthesia and Pain Medicine (ASRA) annual meeting, researchers at Hospital for Special Surgery (HSS) presented two studies focused on glucagon-like peptide-1 (GLP-1) agonist usage in patients undergoing surgery. GLP-1 agonists are a class of medications commonly prescribed to treat type 2 diabetes and obesity, and their therapeutic potential is extending to a range of conditions including cardiovascular and neurodegenerative...